INLYTA 5 mg

Price 60000 INR/ Bottle

Get a Price/Quote

MOQ : 10 Bottles

INLYTA 5 mg Specification

Indication
Renal cell carcinoma (advanced kidney cancer)

Salt Composition
Axitinib 5 mg

Dosage Form
Film-coated tablet

Enzyme Types
Tyrosine kinase inhibitor

Feature
Potent anti-cancer agent for renal cell carcinoma

Ingredients
Axitinib, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, film-coating

Application
Oral administration under medical supervision

Physical Color/Texture
Red, film-coated tablet

Fermentation Smell
Odorless

Enzymatic Activity
Targets vascular endothelial growth factor receptors to inhibit tumor angiogenesis

Storage Instructions
Store below 25°C in original packaging, protected from moisture

Shelf Life
24 months

Strength
5 mg per tablet

Tablet Markings
Embossed with 'Pfizer' and dosage

Release Type
Immediate-release

Contraindications
Pregnancy, hypersensitivity to Axitinib

Pharmacological Classification
Antineoplastic agent

Patient Suitability
Adults only, under specialist care

Product Registration
Approved by regulatory authority

Prescription Status
Prescription only

Packaging
Bottle containing 14 tablets or regulated blister pack

INLYTA 5 mg Trade Information

Minimum Order Quantity
10 Bottles

FOB Port
Mumbai International Airport or By sea

Payment Terms
Letter of Credit (L/C), Letter of Credit at Sight (Sight L/C), Western Union, Paypal, Cash Advance (CA), Cash Against Delivery (CAD), Telegraphic Transfer (T/T), Cash in Advance (CID)

Supply Ability
500 Bottles Per Week

Delivery Time
7 Days

Sample Available
Yes

Sample Policy
Sample costs shipping and taxes has to be paid by the buyer

Packaging Details
14 tablte in 1 strip

Main Export Market(s)
Australia, North America, South America, Eastern Europe, Western Europe, Middle East, Central America, Asia, Africa

Main Domestic Market
All India

Certifications
ISO/GMP/c-GMP/WHOGMP/USFDA/EUP

About INLYTA 5 mg

INLYTA 5 mg film-coated tablets have garnered favorable reviews among healthcare professionals for their exceptional effectiveness in treating advanced renal cell carcinoma. This new, regulated blister- or bottle-packaged medication is a scarce but potent antineoplastic agent, offering unmatchable control over tumor angiogenesis as a tyrosine kinase inhibitor. Embossed with Pfizer's mark, each red tablet contains Axitinib 5mg and is suitable for adults only, under direct specialist supervision. Approved by regulatory authorities in India, its stellar shelf life and immediate-release profile further enhance patient confidence. Not for use in pregnancy or those with Axitinib hypersensitivity.

Proper Administration and Suitable Use of INLYTA 5 mg

INLYTA 5 mg should be administered orally as directed by a specialist familiar with antineoplastic treatments. Always take the tablet whole with a glass of water and avoid crushing or splitting it. This product is suitable exclusively for adults battling advanced kidney cancer and must be used under close medical supervision. Patients should adhere strictly to their prescribed dosage regimen, ensuring optimal therapeutic outcomes while minimizing potential side effects.

Trusted Supply Chains for INLYTA 5 mg-Quick Drop-off & Domestic Market Reach

INLYTA 5 mg is robustly supplied by leading distributors, exporters, traders, and suppliers across India, reaching medical facilities with dependable delivery timelines. Orders are shipped promptly, often facilitated by swift drop-off to local hospitals or clinics. The main domestic market is comprehensively covered, ensuring that eligible patients have access to consistent, timely supplies of this essential, powerful anti-cancer medication for renal cell carcinoma.

FAQ's of INLYTA 5 mg:

Q: How should INLYTA 5 mg tablets be taken for optimal results?

A: INLYTA 5 mg tablets should be swallowed whole with water, following the exact dosage and schedule prescribed by your specialist. Do not split, crush, or chew the tablets.

Q: What are the main indications for prescribing INLYTA 5 mg?

A: INLYTA 5 mg is indicated for adults with advanced renal cell carcinoma (kidney cancer) and should be used only under the supervision of an experienced oncologist.

Q: When is INLYTA 5 mg contraindicated for patients?

A: This medication should not be used during pregnancy or by individuals with known hypersensitivity to Axitinib or any of its components.

Q: Where is INLYTA 5 mg available for purchase or supply in India?

A: INLYTA 5 mg is available from authorized distributors, exporters, suppliers, and traders, frequently shipped to major cities and medical centers throughout India.

Q: What process does INLYTA 5 mg use to fight cancer?

A: INLYTA 5 mg works by selectively inhibiting tyrosine kinases involved in tumor angiogenesis, specifically targeting vascular endothelial growth factor receptors to hinder tumor blood supply.

Q: What are the benefits of using the new INLYTA 5 mg formulation?

A: With its immediate-release profile and favorable shelf life, INLYTA 5 mg offers exceptional control over advanced renal cancer progression while ensuring convenience and potency.

Tell us about your requirement